There’s no notification yet!
Science Keynote, Ethan Russo, MD presents “”Cannabis and Psychiatry The Final Frontier”” at CannMed 2022. Cannabis has been utilized throughout history to treat grief, pain, sleep disorders and even mental illness. The discovery of the endocannabinoid system and its critical role in neurotransmission and homeostasis of the limbic system and other brain areas provide a … Read more
Ethan Russo M.D Cornell University/USDA-ARS National Hemp Webinar Series March 23, 2022
This short educational video provides a concise overview of the endocannabinoid system, along with important facts on the mechanisms of action of hemp oil constituents.
Irritable bowel syndrome (IBS) global burden is underestimated despite its high prevalence. It’s a gastrointestinal disease having obscure pathophysiology with multiple therapies yet unsatisfactory remedies.
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published data in this area. Methods: A systematic search of PubMed and EMBASE (including MEDLINE) was conducted … Read more
The identification and cloning of the two major cannabinoid (CB1 and CB2) receptors together with the discovery of their endogenous ligands in the late 80s and early 90s, resulted in a major effort aimed at understanding the mechanisms and physiological roles of the endocannabinoid system (ECS).
Background: Open-label studies are not ideal for providing robust evidence for long-term maintenance of efficacy of medicines, especially where medicines provide symptom relief and where long-term use of a placebo may be problematic and not ethical.
Background: Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo‐controlled study of an oral antispasticity agent to use an enriched study design.
